TX-MAVENIR
26.8.2020 15:02:13 CEST | Business Wire | Press release
Mavenir, the industry's leading end-to-end cloud-native network software provider for CSPs, and Turkcell, Turkey’s leading digital operator today announce the world’s first OpenRAN vRAN call fully containerized with O-RAN Split 7.2 architecture, in Turkey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005247/en/
Running on Turkcell’s Telco Cloud environment, Mavenir’s OpenRAN vRAN is integrated with Turkcell Core, and is the first workload that will be going live on Turkcell’s Edge Cloud.
Mavenir’s award winning OpenRAN vRAN solution centralizes baseband processing in cloud-native virtualized and containerized baseband units (vBBU) and exploits fronthaul over ethernet between vBBU and multiple remote radio units (RRU). The Mavenir vRAN architecture and platform supports 4G as well as both 5G NR NSA and SA. The vBBU is split into Central Unit (CU) and Distributed Unit (DU) and it features O-RAN standard interfaces.
The split between the DU and the RRU gives flexibility to the RAN system by enabling an efficient interface which can be run over Ethernet and allows concentration of the processing power either into data centers or onto edge platforms. Mavenir’s OpenRAN vRAN allows a very secure and transparent interface which is based on a single architecture that can accommodate several deployment scenarios.
With these open interfaces, as well as virtualization and web scale containerization, the solution has the flexibility to support various deployment scenarios – including Public Cloud, Private Cloud and at the RRU site. It can also support massive MIMO, mmWave, edge micro services and network slicing for 5G NR.
“Mavenir is extremely proud to have supported Turkcell, which is a very innovative and advanced operator, in achieving this first call in a truly OpenRAN containerized implementation,” said Mikael Rylander, Mavenir’s SVP/GM Radio Access Products. “The standard O-RAN 7.2 interface will enable and boost the OpenRAN ecosystem significantly by allowing many RRU vendors to be deployed and to have very effective solutions in all possible frequency bands with great deployment flexibility and with automation and remote operations.”
“We strongly believe in Turkcell that innovation is the engine that allows us to be very close to our customers and meet their demands,” Gediz Sezgin, Turkcell CTO stated. “Now with OpenRAN, we are entering a new era that offers us new ways of deploying Radio Networks and create a real distributed 5G network to fulfill the expectations that the industry has. We are pleased to pioneer this technology with Mavenir by realizing world’s first containerized implementation with a truly open architecture using a mix and match of Open FH supported RRU and CU/DU which reflects the true sense of Open RAN.”
Turkcell is also transforming its LTE and 5G voice network into 100% virtual infrastructures. Mavenir was selected by Turkcell to deploy its cloud-native, NFV-based IMS solution, in Turkcell’s home country Turkey and other subsidiaries.
Mavenir’s Virtualized IMS (vIMS) solution is designed to fully support LTE use cases and evolve into a fully web-scale platform that can meet the requirements enabling Turkcell to continue to lead the evolution to its 5G networks.
About Turkcell:
Turkcell is a digital operator headquartered in Turkey, serving its customers with its unique portfolio of digital services along with voice, messaging, data and IPTV services on its mobile and fixed networks. Turkcell Group companies operate in 5 countries – Turkey, Ukraine, Belarus, Northern Cyprus, Germany. Turkcell launched LTE services in its home country on April 1st, 2016, employing LTE-Advanced and 3 carrier aggregation technologies in 81 cities. Turkcell offers up to 10 Gbps fiber internet speed with its FTTH services. Turkcell Group reported TRY6.9 billion revenue in Q220 with total assets of TRY47.0 billion as of June 30, 2020. It has been listed on the NYSE and the BIST since July 2000, and is the only NYSE-listed company in Turkey. Read more at www.turkcell.com.tr
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider for 4G and 5G, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom